Completed PHASE2 INTERVENTIONAL NCT00189787

Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma

Sponsor: Astellas Pharma Europe B.V.

Conditions Asthma, Bronchial Bronchial Asthma

Interventions tacrolimus

Updated 8 times since 2017 Last updated: Apr 15, 2008 Primary completion: Aug 31, 2005 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Asthma, Bronchial and Bronchial Asthma, this trial is completed. The trial is conducted by Astellas Pharma Europe B.V. and has accumulated 8 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Feb 2026 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Europe B.V.
Astellas Pharma Inc

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Bialystok, Poland , Bonn, Germany , Brno, Czechia , Budapest, Hungary , Csorna, Hungary , Deggendorf, Germany , Dnipro, Ukraine , Donetsk, Ukraine , Düsseldorf, Germany and 27 more locations